ADVANCED SOLID TUMORS

This study tests a new drug called EIK1005, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if the combination can shrink tumors. About 160 adults with certain ca…

This early-stage study tests a new drug, SIM0505, in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the right dose. About 414 people will take part across multiple centers.

This study tests an experimental drug called AMT-253 in people with advanced melanoma or other solid tumors that have spread or cannot be removed by surgery. Participants must have already tried at least one standard treatment without success. The goal is to see if the drug can s…

This early-stage study tests a new drug called HS-20122 in about 1,050 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. This is a first-in-human trial, so the drug's effectivenes…

This early-stage study tests a new drug called HRS-3802 in 100 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants will receive the drug …

This early-stage study tests a new drug called ASP1002 in about 210 adults whose solid tumors have spread or can't be removed. The drug targets tumors with high levels of a protein called claudin 4. The main goals are to check safety, find the best dose, and see if the drug can c…

This study tests a new drug called ASKG915, alone or with standard treatments, in people with advanced solid tumors that have not responded to other therapies. The main goals are to check safety and find the right dose. About 594 participants will take part in this early-phase tr…

This study tests a new drug, HRS-4642, combined with other cancer treatments in people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to find the safest dose and see if the combination shrinks tumors. About 118 adults aged 18-75 with good performa…

This early-phase study tests a new cell therapy called GK01 in 10 people with advanced solid tumors (lung or esophageal cancer) that no longer respond to standard treatments. The main goal is to check safety and side effects, while also looking at how the therapy behaves in the b…

This early-phase trial tests a new drug called metarrestin in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if it can shrink tumors or stop them from growing further. The study includes adults with certain cancers and children aged 12…

This early-stage study tests a new drug called BAT8008 in about 182 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. Participants receive the dru…

This early-stage trial tests a new drug called DT-7012, alone or with another cancer drug, in adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and can shrink tumors. About 125 people will take part.

This early-stage study tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to check safety and find the right dose, wh…

This early-stage study tests an experimental drug, REGN10597, alone or with another drug (cemiplimab) in people with advanced solid tumors like melanoma and kidney cancer. The main goals are to check safety, find the right dose, and see if the drugs shrink tumors. About 240 parti…

This early-phase study tests an experimental pill called ATX-295 in people with advanced solid tumors, including ovarian and breast cancers that have not responded to standard treatments. The drug works by blocking a protein (KIF18A) that cancer cells need to divide. The main goa…

This study tests a new drug, SKB105, in 256 adults with advanced solid tumors that have not responded to standard treatments or are not eligible for them. The trial has three stages to find the best dose and see if the drug shrinks tumors or slows cancer growth. The main goals ar…

This early-stage study tests a new drug called FID-022 in about 24 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and identify any side effects. Participants will receive the drug and be closely monitored for…

This early-stage study tests a new drug called PHST001, alone or with chemotherapy, in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety and find the best dose. The study includes people with ovarian, endomet…

This study tests a new drug called CKD-703 for people with advanced solid tumors or a type of lung cancer (non-small cell lung cancer) that has not responded to standard treatments. CKD-703 is designed to deliver a powerful chemotherapy drug directly to cancer cells that have a s…

This early-stage study tests a virus (JNJ-87704916) that is injected directly into tumors to kill cancer cells. It is being tested alone and with another drug (cetrelimab) in people with advanced solid tumors who have run out of standard treatments. The main goals are to check sa…

This early-stage study tests a new drug called TGW101 in about 50 adults with advanced solid tumors that have worsened after standard treatments. The main goal is to check safety and find the best dose. Researchers will also look at how the drug moves through the body and whether…

This study tests a new drug called CS2009, which targets three different proteins on cancer cells to help the immune system fight tumors. It is for people with advanced solid tumors that have not responded to other treatments. The trial has two parts: first, finding the safest do…

This early-phase study tests a new drug called MGC028 in adults with advanced solid tumors (like lung, bile duct, pancreas, or colon cancer) that have not responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink or control the cancer…

This early-stage study tests an experimental drug called BMS-986504 in 32 Japanese and Chinese adults with advanced solid tumors that have a specific genetic change (MTAP deletion). The main goals are to check the drug's safety and how the body processes it. Participants must hav…

This early-phase study tests a new treatment for people with advanced solid tumors that have not responded to standard therapies. Doctors take immune cells from a patient's own tumor, grow them in a lab, and infuse them back into the patient. The goal is to see if this approach i…

This early-phase study tests a new drug (AT1019) given with targeted radiation and an immunotherapy drug in people with advanced solid tumors that have not responded well to prior treatment. The main goal is to find the safest dose and check for side effects. About 12 adults will…

This study tests a new drug, CM518D1, in about 434 adults with advanced solid tumors that have not responded to other treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or slow their growth. Participants will receive the drug and be closely m…

This early-stage study tests an experimental drug called HDM2006 in about 48 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the right dose. Researchers will also look for early signs that th…

This early-stage study tests a new oral drug, TYRA-430, in people with advanced liver cancer or other solid tumors that have specific genetic changes (FGF/FGFR pathway). The main goals are to find a safe dose and check for side effects. About 100 adults will take part, and the st…

This study tests a new drug called DB-1311 in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if it can shrink tumors. About 862 adults will take part in this early-phase trial across multiple centers.

This early-stage trial tests a new drug called BTM-3566 in 30 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find safe doses and understand side effects. Participants take the drug for 7 days followed by a 7-day break, repeat…

This study tests a new combination of drugs (RAS(ON) inhibitors plus ivonescimab) in adults with advanced or metastatic solid tumors that have a RAS mutation. The goal is to see if the combination is safe and can shrink tumors or slow their growth. About 370 people with cancers l…

This early-phase study tests an experimental drug called JNJ-87890387 in people with advanced solid tumors (kidney, ovarian, uterine, colorectal, or lung cancer) that have spread or cannot be removed. The main goals are to find a safe dose and check for side effects. About 200 pa…

This early-phase study is testing a new drug called GenSci143 in 180 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants will receiv…

This early-phase study tests a new drug called SKB500 in 180 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look at whether the drug can shrink tumors. Pa…

This early-phase study tests a new drug, VVD-159642, designed to block key signals that help cancer cells grow. It is for people with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have not responded to other treatments. The study will first find a safe …

This study allows people with advanced solid tumors who have a specific KRAS gene mutation (G12C) to keep receiving the drug sotorasib (alone or with panitumumab) after their original clinical trial ends. The goal is to monitor safety and side effects for those who are still bene…

This early-stage study tests a new drug, SKB445, in 126 adults with advanced solid tumors who have no standard treatment options. The main goal is to check safety and find the right dose, while also seeing if the drug can shrink tumors. Participants receive the drug by injection …

This study tests a new drug called JAB-23E73 in adults with advanced solid tumors that have a specific genetic change (KRAS alteration). The goal is to find a safe dose and see if it can shrink tumors. About 294 participants will take the drug by mouth, and researchers will monit…

This study tests a new drug, YL205, in 252 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. It is an early-phase trial, so the focus is on safety and dosing, not a…

This early-stage study tests a new drug called HWS116 in about 56 adults with advanced solid tumors (like colorectal, gastric, or pancreatic cancer) that have not responded to standard treatments. The main goals are to check the drug's safety and see if it can shrink tumors. Part…

This early-phase study tests a new drug called 177Lu-RAD202, which is a radioactive antibody that seeks out and attaches to HER2 proteins on cancer cells. The goal is to see if it is safe and to find the right dose for people with advanced solid tumors that have not responded to …

This early-phase study tests a new treatment called Meta10-TIL for people with advanced solid tumors that have not responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in the lab to better attack cancer. The main goal is to check sa…

This study tests an experimental drug called SHR-A1904 in about 83 people with advanced solid tumors (stomach or pancreatic cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. …

This early-stage study tests an experimental drug called SHR-3821 in 162 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the right dose, and see if it helps control the cancer. Participants receive…

This study tests a new drug called SPH4336, either alone or combined with another drug (cadonilimab), in people with advanced solid tumors, including a type of fat tissue cancer (liposarcoma). The goal is to see if the treatment can slow or stop cancer growth. About 63 participan…

This early-phase trial tests a new drug, TEV-56278, alone or with pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 240 participa…

This early-phase study tests a new drug, YL211, in about 155 adults with advanced solid tumors that have not responded to standard treatments. The study has three parts to find the safest dose and check for side effects, while also looking at whether the drug can shrink tumors. P…

This early-phase study tests an experimental drug called ABX-001, given alone or with the immunotherapy pembrolizumab, in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if the…

This study tests a new drug called ETX-636 for people with advanced solid tumors (including breast cancer) that have a specific genetic change called PIK3CA. The drug is designed to block a faulty protein that helps cancer grow. The study will check if the drug is safe and works,…

This early-stage study is testing a new drug called SYN818 combined with olaparib in adults with advanced solid tumors (like ovarian or breast cancer) that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. About 110 part…

This early-phase study tests a new drug, JMKX005425, in about 102 adults with advanced solid tumors that have high microsatellite instability or mismatch repair deficiency. The main goal is to check safety and find the right dose. Researchers will also look at how the drug moves …

This early-stage study tests a new drug called SBO-154 in 177 adults with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The main goals are to check the drug's safety and find the right dose. Researchers will also look for signs that the …

This early-phase study tests a new drug called AK146D1 in about 200 adults with advanced solid tumors that have worsened after standard treatments. The drug is designed to attach to two cancer-related targets (Trop2 and Nectin4) and deliver a toxic payload directly to tumor cells…

This early-phase study tests an experimental drug called MK-0472, given alone or with other cancer drugs (pembrolizumab or MK-1084), in people with advanced solid tumors that have spread. The main goals are to check safety, find the right dose, and see if the drug helps control t…

This study tests a new drug, TUB-030, in adults with advanced solid tumors like head and neck, lung, breast, and colorectal cancers. The main goals are to find a safe dose and see if the drug can shrink tumors. Participants receive the drug every 3 weeks and are closely monitored…

This early-stage study tests a new drug called RMC-5127 in adults with advanced solid tumors that have a specific KRAS G12V gene change. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 574 people with lung, colorectal, or panc…

This early-phase study tests a new drug called ACR246 in people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find a safe dose and check for side effects. About 77 adults aged 18 to 75 will take part.

This early-stage trial tests a new drug called FS-8002 in 66 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look at how the drug moves through the body and …

This early-phase study tests a new drug called FORX-428 in people with advanced solid tumors that have BRCA1/2 mutations or other DNA repair problems. The main goals are to find a safe dose and check for side effects. About 40 adults whose cancer has worsened after standard treat…

This study tests an experimental mRNA treatment (mRNA-4359) alone or with standard immunotherapies in people with advanced solid tumors that have not responded to other treatments. The goal is to find the safest dose and see if it can shrink tumors or slow disease progression. Ab…

This study is for people with advanced solid tumors that cannot be removed by surgery or have spread. It tests a combination of sirolimus (a targeted drug) with different antibody-drug conjugates (ADCs) to see if it is safe and works. About 444 adults aged 18 to 75 will take part…

This study tests a new drug called MB0151 in adults with advanced solid tumors, including certain lung, breast, and neuroendocrine cancers. The goal is to find a safe dose and see if it can shrink or control tumors. About 156 participants will receive the drug intravenously every…

This early-stage trial tests a new drug called Hemay181 in 24 adults with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The main goal is to see if the drug can shrink tumors and to check for side effects. Participants will …

This early-stage study tests a new treatment called NK042, which uses specially designed immune cells to fight advanced solid tumors that have not responded to standard therapies. About 76 adults aged 18 to 70 will receive the treatment to check for safety and any signs of tumor …

This study tests a new drug called FL115 combined with an immunotherapy (PD-1 blocker) in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and can shrink tumors or slow their growth. About 130 adults w…

This study tests a new drug called SPR1020 in people with advanced solid tumors that have not responded to other treatments. The drug is designed to target cancer cells with specific genetic changes while causing fewer side effects than older similar drugs. The trial will first f…

This early-stage study tests a new pill called ZX-8177 in about 80 Chinese adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants will take …

This early-phase study tests a new drug called FP008 in people with advanced solid tumors that have not responded to other treatments. The main goal is to check safety and find the right dose. About 108 adults will take part, and researchers will also look at how the drug works i…

This early-phase study tests a new tablet called GEN-725 in 48 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants must be between …

This study tests a new treatment for people with advanced solid tumors that have not responded to standard therapies. The treatment combines a modified virus (hV01) that targets and kills cancer cells while boosting the immune system, with an immunotherapy drug (tislelizumab) tha…

This early-stage study tests an experimental oral drug, VVD-133214, in people with advanced solid tumors that have specific genetic changes (MSI or dMMR). The drug works by blocking a protein called Werner that helps these cancers grow. The main goals are to check the drug's safe…

This early-phase study tests a new drug called INCA33890 in about 408 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants m…

This study tests a new experimental drug called CKD-512, given alone or with another cancer drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for early signs of tumor shrinka…

This early-phase study tests a new drug called BGM-2121 in about 35 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. Researchers will monitor side effects and look for early signs…

This study tests a new drug called LCB84, which targets a protein (TROP2) on cancer cells, in people with advanced solid tumors that have not responded to standard treatments. The drug is given alone or with an immunotherapy (anti-PD-1) to see if it is safe and can shrink tumors.…

This early-phase study tests a new drug called BG-C477, alone or with other cancer treatments, in people with advanced solid tumors that have not responded to standard therapies. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About …

This early-stage study tests a new drug called BMS-986490, alone or with bevacizumab, in people with advanced solid tumors that have a specific marker (CEACAM5). The main goals are to check safety and find the right dose. About 360 adults with certain cancers (like colorectal or …

This early-phase study tests a new drug called SKB315 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 246 participants will receive the drug …

This early-stage study tests a new drug, SIBP-A19, in 156 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see how the drug moves through the body. Participants will receive the drug and …

This study tests an experimental drug called GFH375 in about 400 adults with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe, how the body processes it, and whether it can shrink tumors. Participants must be 18-75…

This early-stage study tests a new drug called PHN-012 in people with advanced colon, pancreatic, or lung cancers that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a cancer-killing agent directly to tumor cells. The m…

This early-phase study tests a new treatment called Meta10-TIL for people with advanced solid tumors that have not responded to standard therapy. The treatment involves taking immune cells from the patient's tumor, modifying them to work better, and giving them back. The main goa…

This study tests a new daily pill, ABP1011T, in people with advanced solid tumors like small cell lung cancer, esophageal cancer, cervical cancer, bladder cancer, and renal cell carcinoma. Participants take one tablet each day on an empty stomach in 21-day cycles. The goal is to …

This study tests a new drug called YL202 combined with other cancer treatments in people with advanced solid tumors, including breast and lung cancer. The goal is to find a safe dose and see if the combination can shrink tumors. About 414 adults aged 18-75 who have already tried …

This early-stage study tests a new injection form of the drug rilvegostomig in about 40 adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for side effects. Participants will r…

This early-phase study tests a new drug called MK-1084 (calderasib) in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The drug is given alone or with other treatments. The main goals are to check safety, how the body processes the drug, an…

This study tests an experimental drug called marlotamig (REGN7075) alone or with cemiplimab (with or without chemo) in people with advanced solid tumors. The goal is to find the safest dose and see if the combination can shrink tumors or slow their growth. About 933 participants …

This early-phase study tests a new drug called ALTA3263 in adults with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a specific KRAS gene mutation. The main goals are to check safety and find the right dose. About 188 people who have tried other tr…

This study tests a new drug called MRG006A in people with advanced solid tumors that have not responded to other treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 343 adults aged 18 to 75 will take part in this early-phase trial across m…

This study tests an oral drug called BAY 2927088 (sevabertinib) in adults with advanced solid tumors that have HER2 gene mutations. The drug aims to block the abnormal HER2 protein and slow or shrink the cancer. About 111 participants will take the drug daily until their cancer w…

This early-stage study tests a new drug called HW071021 in 76 adults with advanced solid tumors that have spread or come back. The main goal is to check safety and find the best dose. Researchers will also look at how the drug moves through the body and whether it can shrink tumo…

This early-phase trial tests an experimental oral drug called ST-01156 in about 171 adults with advanced solid tumors, including Ewing sarcoma, liver cancer, and bile duct cancer. The drug works by breaking down a protein inside cancer cells. The main goals are to find a safe dos…

This early-stage trial tests a new antibody called GEN1079 in about 121 people with certain advanced solid tumors. The main goal is to check safety and find the best dose. Participants receive the active drug, not a placebo, and are monitored closely with blood tests and scans ov…

This study tests a new drug called GW5282 in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 203 adults will take part in this early-phase trial.

This early-stage study tests a new drug called SIGX1094R in about 102 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants will receive th…

This early-phase study tests a new drug, OKI-219, designed to block a specific cancer-driving mutation (PI3KαH1047R) found in some advanced solid tumors and breast cancers. About 200 adults whose cancer has this mutation will receive OKI-219 alone or combined with other anti-canc…

This study tests a new drug called MK-3120 in people with advanced solid tumors that have spread and cannot be removed by surgery. The main goal is to see if the drug is safe and tolerable. About 270 adults who have tried all other available treatments will take part.

This study tests an experimental drug called BMS-986482, given alone or with other treatments, for people with advanced solid tumors that have not responded to standard therapies. The main goals are to check safety and find the right dose. About 413 adults will take part. The stu…

This early-phase study tests a new drug called GenSci139 in 280 adults with advanced solid tumors that have spread. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study has two parts: first to find a safe dose, then to test…

This early-stage trial tests a new drug called E303 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein called nectin-4 found on many cancer cells. The main goals are to check safety and see if the drug can shrink tumors…

This study tests a new medicine called SNV4818 for people with advanced solid tumors that have a specific genetic change (PIK3CA mutation). The goal is to see if it is safe and works against the cancer. About 320 adults whose cancer has not responded to other treatments will rece…

This study is testing a new drug combination (YL201 and ivonescimab) in people with advanced solid tumors, including certain lung cancers. The goal is to see if the combination is safe and can shrink tumors. About 260 adults will take part, and the study is currently recruiting.

This study tests an experimental pill called WJ22096 in people with advanced solid tumors (like lung, colon, or pancreatic cancer) who have run out of standard options. The trial has three parts: first finding a safe dose, then checking how well that dose works in a small group, …

This study tests a new drug called WEF-001 in people with advanced solid tumors that have a KRAS mutation, including pancreatic, colorectal, and lung cancers. The goal is to check the drug's safety, find the right dose, and see if it shrinks tumors. About 110 adults whose cancer …

This study tests an experimental drug called OTP-01 in people with advanced solid tumors that have not responded to other treatments. The drug targets two proteins (PD-1 and VEGFR2) to help the immune system fight cancer and block tumor blood supply. The main goals are to find th…

This study tests an experimental drug called WJB001 in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 210 adults will take part in three phases: finding the right dose,…

This study tests an experimental drug called RMC-6236 in about 754 adults with advanced solid tumors that have specific RAS gene mutations, including certain lung, colorectal, and pancreatic cancers. The main goals are to check the drug's safety and find the right dose. Participa…

This study tests an experimental drug, VIB305, in people with advanced solid tumors that have not responded to or cannot be treated with standard therapies. The trial has two parts: first, finding the safest dose, and then testing that dose in more patients to see if it shrinks t…

This study tests a new drug called SKB518 for the first time in humans. It is for adults with advanced solid tumors that have stopped responding to standard treatments or have no effective therapy available. The main goals are to check the drug's safety, find the best dose, and s…

This study tests a new drug called SHR-1826 combined with other cancer treatments for people with advanced solid tumors that have not responded to standard therapy. The goal is to find the safest dose and see if the combination can shrink tumors or slow their growth. About 876 ad…

This early-phase study tests a new treatment called CAR-DC for people with advanced solid tumors (cancers that have spread). The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that have certain markers. The main goals are to chec…

This early-stage study tests a new drug called GenSci140 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 170 participants in China will tak…

This study tests a new drug called ALK201 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the best dose. About 202 adults will take part in this early-phase trial.

This study is the first time VVD-130037 is being tested in humans. It aims to find out if the drug is safe and can shrink tumors in people with advanced solid cancers that have stopped responding to standard treatments. About 290 participants will receive the drug alone or combin…

This early-stage study tests a new drug called GS-2121, given alone or with another drug (zimberelimab), in adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the best dose. About 154 participants will take …

This study is testing whether a combination of two drugs, sacituzumab govitecan and berzosertib, can help shrink tumors in people with aggressive cancers that have stopped responding to standard treatments. It is for adults with specific cancers, including small cell lung cancer …

This is the first study in people testing an experimental pill called PAS-004 for advanced solid tumors that have specific genetic mutations (RAS, NF1, or RAF) or have stopped responding to standard treatments. The main goals are to find a safe dose, understand the side effects, …

This early-stage trial is testing a new radioactive drug called HRS-6768 in people with advanced solid tumors that have stopped responding to standard treatments. The study aims to find a safe and effective dose while checking how the drug moves through the body and delivers radi…

This early study is testing a new imaging agent called FL-261 to see if it can safely and accurately detect and stage several types of cancer, including lung, colorectal, and head & neck cancers. The agent targets a protein (c-MET) found on many cancer cells but not on most healt…

This study tests whether wearing a compression stocking on one foot during antibody-drug conjugate (ADC) infusions can prevent nerve damage (peripheral neuropathy). About 58 adults with advanced cancers like bladder cancer will take part. Each person will wear a stocking on their…

This study looks at how the antifungal drug itraconazole changes the way the body processes the experimental cancer drug HS-20093. It involves 18 adults with advanced solid tumors who have not responded to or cannot tolerate standard treatments. The goal is to measure drug levels…

This study looks at whether cancer drugs that target specific gene changes in a tumor can help people with advanced cancers that have not responded to standard treatments. About 720 adults with solid tumors, multiple myeloma, or certain lymphomas will receive a drug matched to th…

This early-phase study looks at how a new drug called rezatapopt affects the way the body processes four common medicines (metformin, rosuvastatin, repaglinide, and midazolam) in people with advanced solid tumors that have a specific TP53 Y220C mutation. About 14 participants wil…

This study looks at how the body processes the cancer drug pralatrexate in people with advanced solid tumors or blood cancers who also have mild, moderate, or severe liver problems. Researchers will measure drug levels in the blood and track side effects to find the safest dose. …

This study looks at whether giving targeted drugs based on a tumor's specific gene changes can help people with advanced cancer who have run out of standard treatments. It includes adults and teens with solid tumors, multiple myeloma, or non-Hodgkin lymphoma. The goal is to learn…